Pancreatic Disorders & Therapy
Open Access

Niu Zuo-xing

Publications

• Review Article
  Stage II Trial of Capecitabine Joined Together with Thalidomide in Second-Line Medicine of Progressed Pancreatic Growth
  Author(s): Shi Sheng-bin, Wang Meng, Niu Zuo-xing, Tang Xiao-yong and Quan Yun-Liu Shi Sheng-bin, Wang Meng, Niu Zuo-xing, Tang Xiao-yong and Quan Yun-Liu
  
  Abstract Background: To assess the viability and averageness of capecitabine joined together with thalidomide in patients with propelled pancreatic disease (APC) who have beforehand accepted gemcitabine-based treatment. Systems: what added up to 31 patients were enrolled prospectively in Shandong Tumor Hospital from May 2007 to April 2009. Capecitabine was offered to patients twice a day at a dosage of 1,250 mg/m2 for 14-days then emulated by 7-day rest. Thalidomide was controlled 100 mg/day without interference until sickness movement or event of inadmissible poisonous quality. Results: Two patients put forth fractional reaction (PR), eleven patients indicated stable ailment (SD) and eighteen patients exhibited continuous illness (PD). The average without movement survival (PFS) was 2.7 months (95% expectancy interim (CI), 2.4-3.3) and the average generally speaking survival (OS) was.. View More»
  DOI: 10.4172/2165-7092.1000109

  Abstract PDF

Relevant Topics